Welcome to our dedicated page for CITIUS ONCOLOGY SEC filings (Ticker: CTOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Citius Oncology, Inc. filings document material-event disclosures for an oncology-focused biopharmaceutical company commercializing LYMPHIR™. Recent Form 8-K reports cover operating and financial results following the LYMPHIR launch, international shipment and distribution updates, clinical-study disclosures involving denileukin diftitox-cxdl, and press-release exhibits related to commercial and medical developments.
The filing record also includes emerging growth company disclosures, Nasdaq continued-listing notice reporting, and categories such as material agreements, shareholder voting matters, capital-structure disclosure, governance matters, and security-structure information. These documents frame CTOR’s public reporting around product commercialization, clinical development, corporate governance, listing compliance, and financing-related matters.
Citius Oncology, Inc. reported that it issued warrants to a financial advisor to purchase up to 360,000 shares of common stock. These warrants have an exercise price of $2.1875 per share, become exercisable on March 10, 2026, and expire on March 10, 2031, and were issued in a private placement under Section 4(a)(2) of the Securities Act.
The board also approved an amendment to the company’s 2024 Omnibus Stock Incentive Plan, increasing the shares of common stock reserved for issuance under the plan from an aggregate of 15,000,000 shares to an aggregate of 30,000,000 shares. Aside from this increase in the share reserve, no other terms of the plan were changed.
Citius Pharmaceuticals, Inc. amended its Schedule 13D to reflect a registered direct offering on September 10, 2025 that issued 5,142,858 new common shares of Citius Oncology, Inc. After that issuance the reporting person, Citius Pharmaceuticals, Inc., beneficially owns 66,049,615 shares, representing approximately 79.1% of the issued and outstanding common stock based on a total of 83,513,442 shares. The filing states the reporting person has sole voting and dispositive power over those shares. The amendment updates prior Schedule 13D filings to give effect to the new issuance.